2 days ago · Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab …

2 days ago · Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susv

1 day ago · F. Hoffmann-La Roche Ltd. Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)

1 day ago · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and …

South San Francisco, CA -- February 4, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration …

Jul 8, 2024 · The US Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level …

Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo …

SUSVIMO ® is clinically proven to deliver vision results equal to monthly injections with just 2 treatments per year.†‡. For patients with wet AMD previously treated with at least 2 intravitreal …

SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 …

1 day ago · The US Food and Drug Administration (FDA) has approved ranibizumab injection) 100 mg/mL (Susvimo; Genentech) for the treatment of diabetic macular edema (DME).The …